A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
← catalyst calendarNCT05548296 · readout in 284 d
Sponsored by Acrivon Therapeutics (industry) · ACRV — their whole pipeline →. With GOG Foundation.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
350estimated
Sites
91
Countries
France, Germany, Italy +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-29 | actual | When the study began enrolling |
| Primary completion | 2027-05-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2022-09-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Endometrial Adenocarcinoma
Interventions
- Drug: ACR-368 — also filed as prexasertib
- Drug: Gemcitabine
- Diagnostic test: OncoSignature
Primary outcomes
what the primary-completion date above is the date OFArm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive.
measured Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative.
measured Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
measured Response will be assessed every 8 weeks from baseline through 2 years or death.
Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers).
measured Response will be assessed every 8 weeks from baseline through 2 years or death.
Permalink · ACRV's whole pipeline · Catalyst calendar · Every registered study · What changed